Precancerous condition

Summary

Precancerous condition (MONDO:0021074) is a disease (an umbrella term covering 8 Mondo subtypes) and 157 clinical trials. Top therapeutic interventions include cidofovir anhydrous, epoetin alfa, and sulindac. A subtype of cancer or benign tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 8 Mondo subtypes
• Clinical trials: 157

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	precancerous condition
Mondo ID	MONDO:0021074
MeSH	D011230
NCIT	C3341
UMLS	C0032927
MedGen	19442
Is cancer (heuristic)	no

Also known as: precancerous condition · precancerous state · premalignant condition · premalignant state

Disease family

This is a subtype of cancer or benign tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › precancerous condition

Related subtypes (4): hyperplasia, polyp, neoplastic disease or syndrome, cancer-related condition

Subtypes (8): pre-malignant neoplasm, in situ carcinoma, neoplastic polyp, intraepithelial neoplasia, leukoplakia, premalignant hematological system disease, gastric intestinal metaplasia, preneoplastic lesion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Eflornithine	Phase 3 (in late-stage trials)
Sulindac	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 157.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	68
PHASE2	37
PHASE1	25
PHASE3	19
PHASE1/PHASE2	6
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002811	PHASE3	UNKNOWN	T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum
NCT00003075	PHASE3	COMPLETED	Fenretinide in Treating Patients With Cervical Neoplasia
NCT00003600	PHASE3	COMPLETED	Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
NCT00005805	PHASE3	COMPLETED	St. John’s Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
NCT00006348	PHASE3	COMPLETED	Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
NCT00027976	PHASE2/PHASE3	WITHDRAWN	Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
NCT00058331	PHASE3	COMPLETED	Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
NCT00078897	PHASE3	TERMINATED	Selenium for Prevention of Adenomatous Colorectal Polyps
NCT00118365	PHASE3	COMPLETED	Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
NCT00128661	PHASE3	COMPLETED	Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
NCT00357682	PHASE3	COMPLETED	A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia
NCT00462813	PHASE3	COMPLETED	Diindolylmethane in Treating Patients With Abnormal Cervical Cells
NCT00655421	PHASE3	UNKNOWN	Oral Cancer Screening in Mumbai, India by Primary Health Care Workers
NCT00661999	PHASE3	COMPLETED	Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
NCT00666211	PHASE3	COMPLETED	Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
NCT00706121	PHASE3	COMPLETED	S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000
NCT00719563	PHASE3	COMPLETED	American Ginseng in Treating Patients With Fatigue Caused by Cancer
NCT01011478	PHASE3	TERMINATED	Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
NCT01164722	PHASE3	COMPLETED	Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
NCT01302834	PHASE3	COMPLETED	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
NCT07150416	PHASE2	NOT_YET_RECRUITING	Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
NCT00002454	PHASE2	UNKNOWN	Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
NCT00002975	PHASE2	COMPLETED	Photodynamic Therapy in Treating Patients With Skin Cancer
NCT00006079	PHASE2	COMPLETED	Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00006466	PHASE1/PHASE2	UNKNOWN	Beta Alethine in Treating Patients With Myeloma
NCT00030264	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
NCT00031759	PHASE2	COMPLETED	Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
NCT00036283	PHASE2	COMPLETED	Chemoprevention of Oral Premalignant Lesions
NCT00060099	PHASE2	UNKNOWN	SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia
NCT00075569	PHASE2	COMPLETED	SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia
NCT00084409	PHASE2	COMPLETED	Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
NCT00101335	PHASE2	COMPLETED	Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
NCT00121173	PHASE1/PHASE2	COMPLETED	Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00132015	PHASE2	COMPLETED	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
NCT00245037	PHASE1/PHASE2	COMPLETED	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT00255749	PHASE2	COMPLETED	Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00281736	PHASE2	COMPLETED	Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer
NCT00314262	PHASE1/PHASE2	COMPLETED	Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
NCT00335504	PHASE2	COMPLETED	Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia
NCT00368927	PHASE2	COMPLETED	Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CIDOFOVIR ANHYDROUS	4	4
EPOETIN ALFA	4	4
SULINDAC	4	4
ONDANSETRON	4	3
AMINOLEVULINIC ACID	4	2
ARTESUNATE	4	2
EFLORNITHINE	4	2
IMIQUIMOD	4	2
PHENYTOIN	4	2
AMIFOSTINE	4	1
ATORVASTATIN CALCIUM	4	1
CELECOXIB	4	1
CETUXIMAB	4	1
DARBEPOETIN ALFA	4	1
FENTANYL CITRATE	4	1
FERROUS SULFATE	4	1
FISH OIL	4	1
FLUDEOXYGLUCOSE F 18	4	1
GADOPENTETATE DIMEGLUMINE	4	1
GANCICLOVIR	4	1
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	4	1
ILOPROST	4	1
INULIN	4	1
LOVASTATIN	4	1
METHADONE HYDROCHLORIDE	4	1
MORPHINE SULFATE	4	1
MOXIFLOXACIN HYDROCHLORIDE	4	1
OXYCODONE HYDROCHLORIDE	4	1
PIRFENIDONE	4	1
RITUXIMAB	4	1